ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2378

Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category

Nicola Ruperto1, Hermine I. Brunner2, Gabriel Vega-Cornejo3, Alberto Berman4, Rubén J. Cuttica5, Francisco Ávila-Zapata6, Michael Henrickson7, Daniel J Kingsbury8, John F. Bohnsack9, Thomas Lutz10, Nadina E Rubio-Pérez11, Valeria Gerloni12, Xiaohui Li13, Marleen Nys14, Robert Wong13, Alberto Martini15 and Daniel J Lovell16, 1Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, 4Centro Médico Privado de Reumatología, Tucumán, Argentina, 5Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 6Star Medica Hospital, Merida, Yucatán, Mexico, 7Cincinnati Children’s Medical Center, Cincinnati, OH, 8Randall Children’s Hospital at Legacy Emanuel, Portland, OR, 9University of Utah School of Medicine, Salt Lake City, UT, 10Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, 11Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, 12Istituto Gaetano Pini, Milan, Italy, 13Bristol-Myers Squibb, Princeton, NJ, 14Bristol-Myers Squibb, Braine L’Alleud, Belgium, 15Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, 16Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Abatacept, Clinical research, juvenile idiopathic arthritis (JIA), pediatrics and polyarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y), SC abatacept (ABA) was effective and well tolerated.1 Here, effectiveness and HRQoL of SC ABA in pts aged 2–17 y by JIA categories over 24 months (M) are presented. Methods: The design of this single-arm, two-cohort, open-label Phase III study (ClinicalTrials.gov, NCT01844518) has been described.1 Eligible pts with JIA received SC ABA (50, 87.5 or 125 mg by body-weight tier) weekly for 4M; JIA-ACR criteria 30% improvement (JIA-ACR30) responders at 4M could receive ABA for another 20M. Pre-specified analyses included JIA-ACR30, 50, 70, 90 and 100 responses and inactive disease (modified criteria)2 status. Post hoc analyses included Juvenile Arthritis Disease Activity Score on 27 joints (JADAS27-CRP) and proportion of pts with minimal clinically important difference (MCID) in Childhood HAQ-DI (CHAQ-DI; MCID −0.188)3 by JIA category (polyarticular [PA] RF positive (+), PA RF negative (−), extended oligoarthritis [EOA], systemic [SA], psoriatic [PsA], enthesitis-related [ERA], persistent oligoarthritis [POA] and undifferentiated [UA] JIA) and overall safety. Due to low pt numbers, separate data for SA, PsA, ERA, POA and UA were not interpreted; data were pooled for JADAS27-CRP. Results: In 219 treated pts, median (min, max) age was 11.0 (2.0, 17.0) y and disease duration was 1.0 (0.0, 15.0) y. Overall, 19.6% of pts discontinued over 24M with 10.0% discontinuing due to lack of efficacy. Data for SA, PsA, ERA, POA and UA are provided for completeness (Figs 1, 2). In PA RF+, PA RF− and EOA, pts responded early to SC ABA and showed robust JIA-ACR30 responses over time (4M: 80.5–96.6%). More stringent JIA-ACR50 (Fig 1), 70, 90 and 100 responses, inactive disease status and JADAS27-CRP (Fig 2) improved across these categories up to M4 and were sustained to M24; similar results were observed in a JADAS27-CRP pooled analysis of other categories. A trend for improvement in CHAQ-DI MCID was evident across categories (24M: 50.0–61.2%). No new/unexpected AEs were observed; a safety summary per age cohort over 24M was reported previously.1

Conclusion: In this analysis of pts aged 2–17 yrs with JIA, SC abatacept was effective and well tolerated and improved HRQoL across JIA categories over 24M.

References: 1. Brunner HI, et al. Arthritis Rheumatol 2018; doi: 10.1002/art.40466. 2. Wallace CA, et al. Arthritis Care Res (Hoboken) 2011;63:929–36. 3. Brunner HI, et al. J Rheumatol 2005;32:150–61. Medical writing assistance provided by Katerina Kumpan, PhD (Caudex), funded by Bristol-Myers Squibb.

   


Disclosure: N. Ruperto, Abbott, AbbVie, Amgen, Biogenidec, Astellas, Alter, AstraZeneca, Baxalta Biosimilars, Boehringer, Bristol-Myers Squibb, CD-Pharma, Celgene, CrescendoBio, EMD Serono, Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, 8,Abbott, Bristol-Myers Squibb,, 2,Rewind Arms, R-Pharma, Sanofi-Aventis, Servier, Sinergie, Takeda, Vertex, UCB Biosciences GmbH, 8; H. I. Brunner, Novartis, Genentech, Pfizer, UCB, Lilly, Janssen, Ablynx, AbbVie, Bristol-Myers Squibb, EMD Serono, Astrazeneca, 5,Genentech and Novartis, 8; G. Vega-Cornejo, None; A. Berman, None; R. J. Cuttica, Abbvie, Bristol-Myers Squibb, Centocor, GSK, Lilly, Novartis, Pfizer, Roche, 5, 8; F. Ávila-Zapata, None; M. Henrickson, None; D. J. Kingsbury, None; J. F. Bohnsack, None; T. Lutz, None; N. E. Rubio-Pérez, None; V. Gerloni, None; X. Li, Bristol-Myers Squibb, 1, 3; M. Nys, Bristol-Myers Squibb, 1, 3; R. Wong, Bristol-Myers Squibb, 1, 3; A. Martini, None; D. J. Lovell, AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Takeda, GlaxoSmithKline, Boehringer Ingelheim, Celgene, Janssen, Hoffmann-La Roche, Wyeth Pharma, Amgen, Abbott, 5,Wyeth Pharma, 8.

To cite this abstract in AMA style:

Ruperto N, Brunner HI, Vega-Cornejo G, Berman A, Cuttica RJ, Ávila-Zapata F, Henrickson M, Kingsbury DJ, Bohnsack JF, Lutz T, Rubio-Pérez NE, Gerloni V, Li X, Nys M, Wong R, Martini A, Lovell DJ. Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/subcutaneous-abatacept-in-patients-aged-2-17-years-with-juvenile-idiopathic-arthritis-and-inadequate-response-to-biologic-or-non-biologic-disease-modifying-antirheumatic-drugs-results-over-24/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneous-abatacept-in-patients-aged-2-17-years-with-juvenile-idiopathic-arthritis-and-inadequate-response-to-biologic-or-non-biologic-disease-modifying-antirheumatic-drugs-results-over-24/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology